Dosimetric Characteristics of Self-expandable Metallic and Plastic Stents for Transpapillary Biliary Decompression in External Beam Radiotherapy

Overview

Journal Phys Eng Sci Med

Publisher Springer

Specialty Biomedical Engineering

Date 2024 Jul 8

PMID 38976186

Authors

Yoshihiro Ueda

Kenji Ikezawa

Tomohiro Sagawa

Masaru Isono

Shingo Ohira

Masayoshi Miyazaki

Ryoji Takada

Takuo Yamai

Kazuyoshi Ohkawa

Teruki Teshima

Koji Konishi

Affiliations

Soon will be listed here.

Abstract

There is little evidence regarding radiation dose perturbation caused by the self-expandable metallic stents (SEMSs) used for transpapillary biliary decompression. We aimed to compare SEMSs with plastic stents (PSs) and clarify their dosimetric characteristics. Fifteen SEMSs (10 braided and 5 lasercut type) and six PSs (diameter: 2.3-3.3 mm) were inserted into a water-equivalent solid phantom. In total, 13 SEMSs had radiopaque markers, whereas the other two did not. Using radiochromic films, the dose difference adjacent to the stents at locations proximal, distal, and arc delivery to the radiation source was evaluated based on comparison to measurement of the dose delivery in phantom without any stent in place. The median values of the dose difference for each stent were used to compare the SEMS and PS groups.Results: The dose difference (median (minimum/maximum)) was as follows: proximal, SEMSs + 2.1% (1.8 / 4.7) / PSs + 5.4% (4.1 / 6.3) (p < 0.001); distal, SEMSs -1.0% (-1.6 /-0.4) / PSs -8.9% (-11.7 / -7.4) (p < 0.001); arc delivery, SEMSs 1.2% (0.9 / 2.3) / PSs 2.2% (1.6 / 3.6) (p = 0.005). These results demonstrated that the dose differences of SEMSs were significantly smaller than those of PSs. On the other hand, the dose difference was large at surface of the radiopaque markers for SEMSs: proximal, 10.3% (7.2 / 20.9); distal, -8.4% (-16.3 / -4.2); arc delivery, 5.5% (4.2 / 9.2). SEMSs for biliary decompression can be safely used in patients undergoing radiotherapy, by focusing on the dose distribution around the stents and by paying attention to local changes in the dose distribution of radiopaque markers.

References

Okusaka T, Furuse J . Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020; 55(4):369-382. PMC: 7080663. DOI: 10.1007/s00535-020-01666-y. View

Philip P, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo J . Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020; 5(3):285-294. DOI: 10.1016/S2468-1253(19)30327-9. View

Ikezawa K, Kiyota R, Takada R, Daiku K, Maeda S, Imai T . Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer. JGH Open. 2021; 5(6):679-685. PMC: 8171163. DOI: 10.1002/jgh3.12555. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A . Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. ESMO Open. 2020; 5(6):e000929. PMC: 7684818. DOI: 10.1136/esmoopen-2020-000929. View

Takada R, Ikezawa K, Daiku K, Maeda S, Abe Y, Urabe M . The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer. Cancers (Basel). 2021; 13(18). PMC: 8470784. DOI: 10.3390/cancers13184733. View

Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiraoka N . Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol. 2020; 51(2):235-243. DOI: 10.1093/jjco/hyaa198. View

Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M . Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013; 258(6):1040-50. DOI: 10.1097/SLA.0b013e31829b3ce4. View

Strobel O, Neoptolemos J, Jager D, Buchler M . Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2018; 16(1):11-26. DOI: 10.1038/s41571-018-0112-1. View

10.

Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F . Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007; 25(3):326-31. DOI: 10.1200/JCO.2006.07.5663. View

11.

Dumonceau J, Tringali A, Papanikolaou I, Blero D, Mangiavillano B, Schmidt A . Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. Endoscopy. 2018; 50(9):910-930. DOI: 10.1055/a-0659-9864. View

12.

Kitano M, Yamashita Y, Tanaka K, Konishi H, Yazumi S, Nakai Y . Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013; 108(11):1713-22. DOI: 10.1038/ajg.2013.305. View

13.

Kaassis M, Boyer J, Dumas R, Ponchon T, Coumaros D, Delcenserie R . Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc. 2003; 57(2):178-82. DOI: 10.1067/mge.2003.66. View

14.

Almadi M, Barkun A, Martel M . Plastic vs. Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses. Am J Gastroenterol. 2016; 112(2):260-273. DOI: 10.1038/ajg.2016.512. View

15.

Ikezawa K, Takada R, Takahashi H, Kiyota R, Imai T, Abe Y . Efficacy of Larger-Diameter Plastic Stent Placement for Preoperative Biliary Drainage in Patients Receiving Neoadjuvant Chemoradiation for Pancreatic Cancer. Pancreas. 2020; 49(3):e20-e21. DOI: 10.1097/MPA.0000000000001509. View

16.

Adams M, Anderson M, Myles J, Khalatbari S, Scheiman J . Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy. J Gastrointest Oncol. 2012; 3(4):309-13. PMC: 3492479. DOI: 10.3978/j.issn.2078-6891.2011.050. View

17.

Nakamura K, Sho M, Akahori T, Nagai M, Nishiwada S, Nakagawa K . A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer. World J Surg. 2018; 43(2):642-648. DOI: 10.1007/s00268-018-4820-6. View

18.

Kubota K, Sato T, Watanabe S, Hosono K, Kobayashi N, Mori R . Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer. Dig Endosc. 2013; 26(1):77-86. DOI: 10.1111/den.12049. View

19.

Atwood T, Hsu A, Ogara M, Luba D, Tamler B, DiSario J . Radiotherapy dose perturbation of esophageal stents examined in an experimental model. Int J Radiat Oncol Biol Phys. 2011; 82(5):1659-64. DOI: 10.1016/j.ijrobp.2011.02.020. View

20.

Chen Y, Schefter T, Newman F . Esophageal cancer patients undergoing external beam radiation after placement of self-expandable metal stents: is there a risk of radiation dose enhancement?. Gastrointest Endosc. 2011; 73(6):1109-14. DOI: 10.1016/j.gie.2011.02.001. View